Overview Shionogi has launched Endeavorride, Japan’s first Software as a Medical Device (SaMD) digital therapeutic app for the adjunctive treatment of pediatric ADHD. The app, l...
Overview Cerebral has acquired Inflow, a personalized ADHD digital therapeutic app, to strengthen its integrated mental healthcare platform and expand continuous support for patients w...
Overview GAIA reported positive results from a randomized controlled trial published in Psychological Medicine, demonstrating that attexis significantly reduced ADH...
Overview Lumos Labs has received FDA 510(k) clearance for LumosityRx, a prescription digital therapeutic (PDT) designed to improve attention in adults aged 22 to 55 with ADHD. Built o...
